Selank vs Semax: Evidence, Legal Status and Key Differences

By Editorial team. Updated Oct 15, 2026. Awaiting expert review

Selank vs Semax at a glance

FactSelankSemax
Also known asSelank acetate, TP-7Semax acetate
What it isSynthetic tuftsin analogueSynthetic ACTH(4-10) analogue (registered in Russia)
Evidence levelEarly human trialsEarly human trials
Approved productsNoneNone
United StatesNot FDA-approved; the nomination of selank for pharmacy (503A) compounding was withdrawn after FDA flagged potential safety risks [12][9].Not FDA-approved; FDA staff recommended against adding semax to the 503A compounding list, and although FDA's advisory committee voted to recommend it in July 2026, FDA has not added it [12][5][21].
United KingdomNo UK-licensed medicine containing selank appears in the MHRA products database [13].No UK-licensed medicine containing semax appears in the MHRA products database [22].
European UnionNo medicine containing selank is authorized in the EU, according to EMA's central and Article 57 product data [14][15].No medicine containing semax is authorized in the EU, according to EMA's central and Article 57 product data [14][15].
CanadaNo product containing selank appears in Health Canada's Drug Product Database [16].No product containing semax appears in Health Canada's Drug Product Database [16].
AustraliaSelank is not named in Australia's Poisons Standard (October 2026) [17].Semax is not named in Australia's Poisons Standard (October 2026) [17].
Sport (WADA)Not named on the 2026 Prohibited List [10].Not named on the 2026 Prohibited List [10].
Vendors we track57 vendors57 vendors
Our lab testsNone yetNone yet
Regulatory rows summarize official sources, checked Oct 15, 2026; rules change, so follow the numbered sources. Not legal or medical advice, and we don't publish dosing or usage instructions.

Selank and Semax are short synthetic peptides developed in Russia [4], and both end in the same three amino acids, Pro-Gly-Pro [2]. The rest of each molecule is different. Selank is built on tuftsin, a fragment of an immune protein, and is listed as an anti-anxiety drug; Semax is built on a fragment of the hormone ACTH and is classed as a nootropic [1, 3, 4]. The human evidence for both is small and comes mostly from studies published in Russian, and neither is an approved medicine in the US, UK, EU or Canada (see the table above).

What each one is

Selank is the seven-amino-acid peptide Thr-Lys-Pro-Arg-Pro-Gly-Pro [2]. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as an analogue of tuftsin, a four-amino-acid fragment of human immunoglobulin G, with Pro-Gly-Pro added to make it more stable in the body [1].

Semax is the seven-amino-acid peptide Met-Glu-His-Phe-Pro-Gly-Pro [2]: a fragment of ACTH (amino acids 4 to 7) joined to the same Pro-Gly-Pro tail [3]. FDA describes it as an analogue of the ACTH(4–10) fragment that is registered as a drug in Russia, where it is available as nasal drops [5].

A 2022 review lists both among the peptide drugs developed in Russia: Selank as an anti-anxiety drug and Semax as a nootropic [4].

Some vendors also sell “N-acetyl” or “amidate” versions, which are modified at the ends of the peptide chain. For Semax, researchers found that adding an acetyl group changes its chemical and biological properties [11]. These are different compounds, so we price them separately: N-acetyl Semax and N-acetyl Selank.

How the evidence compares

Selank. The clinical studies we found were published in Russian, and the two summarized here are small [6, 7]. Both compared Selank with a benzodiazepine, and neither abstract describes a placebo group [6, 7]. In 62 patients with generalized anxiety disorder or neurasthenia, its anti-anxiety effect was reported to be similar to medazepam’s [6]. In 60 patients with anxiety disorders compared with phenazepam, the anti-anxiety effect was reported to last a week after treatment ended [7]. Other work is in rats, including a study of genes involved in GABA signaling in the brain [1].

Semax. The human evidence is also small. A 1997 Russian study compared 30 patients given Semax in the acute phase of ischemic stroke with 80 conventionally treated patients [8]. In rats, Semax increased the activity of genes for neurotrophins, proteins that support nerve cells, after an experimental stroke [3]. Reviewing it for compounding in 2026, FDA found that the available references on cerebral ischemia, migraine and trigeminal neuralgia showed a lack of effectiveness and were limited by small sample sizes [5].

One 2001 laboratory study found that both peptides blocked enzymes in human serum that break down enkephalins, the body’s own opioid peptides [2]. That is a test-tube result, not evidence of an effect in people.

Regulation and sport

Neither is an approved medicine in the US, UK, EU or Canada. FDA had placed both in category 2, its group of bulk substances that may present significant safety risks in compounding, and now lists them as nominations withdrawn by their nominators [9]. Neither is named on WADA’s 2026 Prohibited List [10].

Quality risks when buying

Research-grade Selank and Semax are not regulated medicines. FDA says compounded versions of both may cause immune reactions because of aggregation and peptide-related impurities, and that it lacks information on their safety in people [9]. For Semax, FDA adds that sources often don’t say whether they mean the free base or a salt, and that it has encountered multiple salts and derivatives sold under the same name [5].

So a certificate of analysis (COA) should name the exact form tested and confirm identity by mass spectrometry, not just report purity. Our guides explain how to read a COA, how to check a vendor and what “research use only” means.

For more on each compound, see our Selank overview and Semax overview, and today’s prices for Selank and Semax.

Frequently asked questions

What is the difference between Selank and Semax?

Both are seven-amino-acid peptides developed in Russia that end in the same three amino acids, Pro-Gly-Pro. Selank is based on tuftsin, a fragment of an immune protein, and was studied for anxiety. Semax is based on a fragment of the hormone ACTH and was studied mainly in stroke.

Are Selank and Semax approved medicines?

Not in the US, UK, EU or Canada. A 2022 review lists both among peptide drugs developed in Russia, and FDA describes Semax as registered there as nasal drops.

Is N-acetyl Semax the same as Semax?

No. N-acetyl and amidate versions are chemically modified forms. Research on N-acetyl Semax found that the change alters its chemical and biological properties, so findings for one form don't automatically apply to the other.

Sources

  1. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission (full text). Frontiers in Pharmacology (2016). Accessed Oct 15, 2026
  2. Semax and selank inhibit the enkephalin-degrading enzymes from human serum (in Russian). Bioorganicheskaia Khimiia (2001). Accessed Oct 15, 2026
  3. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology (2010). Accessed Oct 15, 2026
  4. Development of Peptide Biopharmaceuticals in Russia (Table 1: peptide drugs developed in Russia). Pharmaceutics (2022). Accessed Oct 15, 2026
  5. FDA Briefing Document: Semax-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026. U.S. Food and Drug Administration. Accessed Oct 15, 2026
  6. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (in Russian). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (2008). Accessed Oct 15, 2026
  7. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders (in Russian). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (2014). Accessed Oct 15, 2026
  8. Effectiveness of semax in acute period of hemispheric ischemic stroke (in Russian). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (1997). Accessed Oct 15, 2026
  9. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). U.S. Food and Drug Administration. Accessed Oct 15, 2026
  10. World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 15, 2026
  11. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. Journal of Inorganic Biochemistry (2016). Accessed Oct 15, 2026
  12. Drugs@FDA: FDA-Approved Drugs (database searched by active ingredient). U.S. Food and Drug Administration. Accessed Oct 14, 2026
  13. MHRA Products: licensed-medicine search for "selank". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 14, 2026
  14. EMA medicines data: centrally authorised human medicines (export of 14 October 2026). European Medicines Agency. Accessed Oct 14, 2026
  15. EMA Article 57 product data: medicines authorised in the EU/EEA (data as of 9 October 2026). European Medicines Agency. Accessed Oct 14, 2026
  16. Drug Product Database online query (searched by active ingredient). Health Canada. Accessed Oct 14, 2026
  17. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 14, 2026
  18. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of Experimental Biology and Medicine (2022). Accessed Oct 14, 2026
  19. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine (2001). Accessed Oct 14, 2026
  20. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology (2016). Accessed Oct 14, 2026
  21. FDA Panel Backs 6 Peptides for Compounding (31 July 2026). AJMC (The American Journal of Managed Care). Accessed Oct 14, 2026
  22. MHRA Products: licensed-medicine search for "semax". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 14, 2026
  23. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. Accessed Oct 14, 2026